Clinical indications for this novel medicine will expand.
Sweaty hands, feet, legs, cholinergic urticaria, excess secretions, bronchospasm, colic, pupillary dilation, motion sickness etc
Botanix market cap of $20B on the back of this clinically useful ultra-short acting anticholinergic.
Ann: FDA Approves Sofdra, page-301
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.020(4.94%) |
Mkt cap ! $698.4M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 38.0¢ | $2.328M | 5.993M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 305870 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 384988 | 14 |
View Market Depth
| Last trade - 13.49pm 18/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |